Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9093)
All Articles published online
|
Publishing Process of This Article
|
Jul 27, 2019 (publication date) through Apr 1, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Dokmak A, Almeqdadi M, Trivedi H, Krishnan S. Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease. World J Hepatol 2019; 11(7): 562-573 [PMID: 31388398 DOI: 10.4254/wjh.v11.i7.562] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v11/i7/562.htm |
| Number | Citing Articles |
| 1 |
Rehab F. Abdel-Rahman. Non-alcoholic fatty liver disease. Asian Pacific Journal of Tropical Biomedicine 2022; 12(3): 99 doi: 10.4103/2221-1691.338919
|
| 2 |
Amélio F. Godoy-Matos, Cynthia Melissa Valério, Wellington S. Silva Júnior, João Marcello de Araujo-Neto, Marcello Casaccia Bertoluci. 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes. Diabetology & Metabolic Syndrome 2024; 16(1) doi: 10.1186/s13098-024-01259-2
|
| 3 |
Hirsh D. Trivedi, Jaspreet Suri, Daheun Oh, Jeffrey Schwartz, Daniela Goyes, Rajab Idriss, Michael P. Curry, Michelle Lai. The presence of diabetes impacts liver fibrosis and steatosis by transient elastography in a primary care population. Annals of Hepatology 2021; 24: 100336 doi: 10.1016/j.aohep.2021.100336
|
| 4 |
Paola Dongiovanni, Erika Paolini, Alberto Corsini, Cesare R. Sirtori, Massimiliano Ruscica. Nonalcoholic fatty liver disease or metabolic dysfunction‐associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. European Journal of Clinical Investigation 2021; 51(7) doi: 10.1111/eci.13519
|
| 5 |
Amr Dokmak, Blanca Lizaola-Mayo, Hirsh D. Trivedi. The Impact of Nonalcoholic Fatty Liver Disease in Primary Care: A Population Health Perspective. The American Journal of Medicine 2021; 134(1): 23 doi: 10.1016/j.amjmed.2020.08.010
|
| 6 |
Georgios S. Papaetis, Michalis K. Picolos, Anastasia Sacharidou. Pioglitazone with SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and non-alcoholic fatty liver disease: could the combinations of an old friend with new players yield better outcomes?. Archives of Medical Science – Atherosclerotic Diseases 2025; 10(1): 1 doi: 10.5114/amsad/202298
|
| 7 |
Mazhar Hussain, Muhammad Zafar Majeed Babar, Saba Tariq, Muhammad Irfan Ahmad, Lubna Akhtar. Therapeutic outcome of dapagliflozin on various parameters in non-alcoholic fatty liver disease (NAFLD) patients. International Journal of Diabetes in Developing Countries 2022; 42(2): 290 doi: 10.1007/s13410-021-00980-2
|
| 8 |
Amélio F. Godoy-Matos, Wellington S. Silva Júnior, Cynthia M. Valerio. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetology & Metabolic Syndrome 2020; 12(1) doi: 10.1186/s13098-020-00570-y
|
| 9 |
György M. Buzás. Helicobacter pylori and non-alcoholic fatty liver disease. Minerva Gastroenterologica e Dietologica 2020; 66(3) doi: 10.23736/S1121-421X.20.02671-9
|